Test with precision,
treat with confidence
By testing the response of a patient’s own cancer cells against 100+ drugs and combinations, we help physicians make more informed treatment decisions.
Next-generation precision medicine
CURRENT STATE:
Genomics can’t solve it all
Most drugs don't have a genomic predictor and most cancer mutations don’t have a matching drug. Additionally, genomic testing uses dead tissue, which can't reveal how live cancers respond to treatment in the body.
The Shift:
Measure actual drug responses
PrevisionOne, our patented ex vivo platform, tests living cancer and healthy cells against a broad panel of drugs and drug combinations before treatment starts. We rank drugs based on their ability to more selectively kill cancer than non-cancer cells.
OUR SOLUTION:
Clinical insights within days
The PrevisionOne clinical report reveals for each patient individually which drugs are effective and which ones cause harm. This saves time and helps oncologists make better informed treatment decisions for improved patient outcomes.
Endorsed by the most reputable in our field
.png)
By integrating PrevisionOne into our clinical workflows, we can identify the most effective therapies for each of our patients. This helps us find the most promising treatment options rapidly, saving crucial time for patients who have run out of standard treatment options. It’s a powerful example of how innovation can transform day-to-day decision-making in the clinic and truly bridge the gap between research and real patient care.
Prof. Dr. med. Thomas Pabst,
Inselspital Bern
Inselspital Bern
Half of Glioblastoma patients die within one year of diagnosis, despite multimodality treatment of surgery, radiotherapy and chemotherapy. Therefore, novel treatment approaches to glioblastoma are urgently needed. Prevision Medicine's innovative approach of ex vivo drug sensitivity profiling offers new hope for patients afflicted by glioblastoma and for their caregivers.
Prof. Dr. med. Michael Weller,
University Hospital Zurich
University Hospital Zurich
Adding functional testing to genomics
Genomic
Testing
Testing
Nucleic acid proxy
Sequencing DNA information from dead tissues
Predicting response
Interpretation of genomic markers and statistical correlations
Limited scope
Less than 20% of drugs have genomic predictors of response
Indication specific
Predictive genomic markers are often specific for a cancer type
Broad application
Used for risk prediction, monitoring and treatment evaluation
Functional
Testing
Testing
Live cell reality
Measuring cellular activity of living cells
Measuring response
Direct measurement of the patient cells' responses to treatment
Unlimited scope
All types of drugs and combinations can be tested
Indication agnostic
Ex vivo drug testing can be done on most cancer types
Actionable clarity
Used for rapid informing of treatment decisions
Our Partners Include
.png)
.png)
Improved outcomes
Proof, not
idle promises
idle promises
Not theories - real outcomes
A brain tumor patient was effectively treated with an antidepressant.
A spinal cancer patient was successfully treated after every standard drug failed.
Several patients with AML in palliative care went into a complete remission upon individual treatment with drugs that had a high score in our test.
New perspectives for patients
Live-cell testing using Prevision's patented approach has uncovered effective treatments for individual patients, even when clinical guidelines failed, options ran out, or standard therapies threatened healthy tissue.
Our PrevisionOne platform supports the treating physicians with patient-specific response data, giving patients new hope and new perspectives.
Our PrevisionOne platform supports the treating physicians with patient-specific response data, giving patients new hope and new perspectives.
How it Works
From test to treatment
1
We receive and prepare your sample
We start with a routine biopsy of blood cancer or solid tumor. Fresh samples are shipped to our lab for immediate preparation and testing.
2
We test 100+ treatments on live cells
Using proprietary drug plates, we expose each patient's living cells to 100+ treatments and combinations - including standard, experimental and off-label drugs.
3
We capture real-time cell response
Through automated microscopy and Al analysis, we track at single-cell level how both cancer and non-cancer cells react to each drug or combination.
4
We deliver a clinical report
Within 3 days, we provide a personalized and easy to interpret report indicating which drugs are most effective at killing the patient's cancer.
Informed treatments extend lives
Know exactly what helps and what harms so you can choose a suitable treatment quickly and confidently.
Have a case in mind?
Credibility & Evidence
Clinically proven.
Peer-reviewed.
Hospital tested.
Prevision's technology is grounded in over a decade of research and was validated through clinical collaborations with over 20 European hospitals and testing of 2000 patient samples.
Latest news
Press Release: Prevision Medicine adds Multiple Myeloma to their personalized drug-testing portfolio
Prevision Medicine has expanded its personalized drug screening platform, PrevisionOne™, to include Multiple Myeloma (MM). The test generates patient-specific drug sensitivity profiles from patient samples, helping oncologists identify the most effective treatment combinations.
.png)
Prevision Medicine joins the Genolier Innovation Network
Prevision Medicine has joined the Genolier Innovation Network, a collaborative ecosystem driving disruptive health innovations. This partnership will foster new opportunities to advance precision oncology and accelerate the future of personalized patient care.
From Prototypes to Impact: Lessons from FutureHealth Lausanne
Two weeks ago, we attended FutureHealth Lausanne - one Europe’s leading conferences on healthcare innovation and digital transformation. Here are the three key insights we took away and what they mean for us at Prevision Medicine.
View the News!
View our latest news updates directly on LinkedIn
Publications
View All Publications
About Us
The values that drive innovation
Prevision Medicine was founded to deliver quick, precise and actionable treatment guidance when options are limited. Our scientists and partners are inspired by our patented, transformational approach to cancer treatment, and we are determined to use it to improve patients’ lives and outcomes.
.png)
Innovation
We challenge the status quo to advance cancer care and tools that improve treatment.
Transparency
We share results openly, communicate clearly, and believe honesty drives better patient care.
Making a Difference
We exist to help patients live longer by giving physicians evidence they can act on confidently.
Quality & Reliability
We follow data, refine rigorously, and deliver results oncologists can count on—every time.
Trust & Integrity
We do what’s right, not what’s easy—because patients are trusting us with their future.
Leadership team
Philip brings over two decades of leadership in health tech ventures. Prior to Prevision, he led his former company, Nebion, to a successful exit with Immunai. Philip brings a wealth of experience to turn strategies into actionable results and to empower high potential teams.
Valentin has spent his career in several successful Techbio start-ups, at the intersection of finance, business development and personalized medicine. At Prevision, he leads the complexity of the operational deployment while focusing on the commercial scale-up.
Yannik has co-invented and led every step of the development of our Al-powered platform that enables Prevision's 3-day turnaround. He is steering the research and development team to leverage the full potential of the technology, for clinical and pharma applications.
Berend is Faculty Professor at the Botnar Institute of Immune Engineering, and previously assistant professor at the ETH Zurich. He is one of the originators of pharmacoscopy, has published extensively in top-tier scientific journals, and is a world leader in functional precision medicine.
Join Prevision
Zurich, Switzerland
We’re always looking for bold, kind, impact-driven people to help us move precision oncology forward. If you’re passionate about solving real-world challenges in healthcare, get in touch.
Site by Whale